Skip to main content

Table 1 Characteristics of study participants

From: Prevalence and antimicrobial resistance profiles of respiratory microbial flora in African children with HIV-associated chronic lung disease

Variable   CLD+ CLD- P
Site Zimbabwe 72% (241/336) 74% (55/74) 0.770
Sex Female 49% (166/336) 62% (46/74) 0.054
Age Median (IQR) 15 (13–18) 16 (12–18) 0.939
Anthropometric
 BMI-for-age  z -score2 Median (IQR) −1.114 (− 1.85, −0.28) − 0.32 (− 0.83, − 0.58) < 0.001
 Height-for-age z-score a <− 2 (Stunted) 50% (168/336) 30% (22/74) 0.002
 Weight-for-age z-score a <−2 (Underweight) 52% (176/336) 19% (14/74) < 0.001
Current drug use
 Cotrimoxazole (CTX)   91% (304/334) 86% (60/70) 0.188
 Antiretroviral regimen λNNRTI-based regimen -1st line 74% (247/335) 89% (65/73) 0.006
  §PI-based regimen-2nd line 26% (88/335) 11% (8/73)
HIV clinical parameters
 CD4 count categories > 500 cells/mm 62% (208/336) 67% (49/73) 0.770
  200–500 cells/mm 28% (94/336) 25% (18/73)
  < 200 cells/mm 10% (34/336) 8% (6/73)
 Viral load (VL) suppression VL < 1000 copies/mL 56% (187/336) 66% (49/74) 0.119
 Age at ART initiation Median (IQR) 8 (6–12) 9 (5–11) 0.667
 Years spent on ART Median (IQR) 6 (4–9) 7 (4–9) 0.571
Respiratory status
 Previously treated for TB, % (N)   29% (97/335) 12% (9/73) 0.003
 FEV1 z-score Median (IQR) −1.96 (−2.46, −1.47) 0.52 (0.23, 0.79) < 0.001
 Admitted for chest problems in last 12 months   2% (6/336) 1% (1/74) 1
 Asthma   3% (11/336) 0% (0/74) 0.227
 MRC dyspnoea Score 1 55% (185/336) 78% (59/73) 0.001
  2 35% (120/336) 16% (12/73)
  3 6% (19/336) 3% (2/73)
  4 3% (10/336) 0% (0/73)
  5 1% (2/336) 0% (0/73)
  1. Participants with missing responses are excluded from that variable. Only one participant (from the CLD group) uses an inhaler. λ Nonnucleoside Reverse Transcriptase Inhibitor, § Protease inhibitor